Achilles Therapeutics PLC Performance
| ACHLDelisted Stock | USD 1.48 0.00 0.00% |
On a scale of 0 to 100, Achilles Therapeutics holds a performance score of 12. The firm shows a Beta (market volatility) of -0.88, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Achilles Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Achilles Therapeutics is expected to outperform it slightly. Please check Achilles Therapeutics' information ratio, downside variance, day typical price, as well as the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Achilles Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Achilles Therapeutics Announces 12M AstraZeneca Deal, Plans Job Cuts | 12/24/2024 |
2 | 12 Health Care Stocks Moving In Tuesdays Pre-Market Session - Benzinga | 02/04/2025 |
3 | Achilles Therapeutics stock hits 52-week high at 1.41 - Investing.com | 03/13/2025 |
| Begin Period Cash Flow | 173.4 M | |
| Free Cash Flow | -49.5 M |
Achilles |
Achilles Therapeutics Relative Risk vs. Return Landscape
If you would invest 115.00 in Achilles Therapeutics PLC on December 26, 2024 and sell it today you would earn a total of 33.00 from holding Achilles Therapeutics PLC or generate 28.7% return on investment over 90 days. Achilles Therapeutics PLC is currently generating 0.478% in daily expected returns and assumes 3.0867% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Achilles, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Achilles Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Achilles Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Achilles Therapeutics PLC, and traders can use it to determine the average amount a Achilles Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1549
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ACHL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.09 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.48 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average Achilles Therapeutics is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Achilles Therapeutics by adding it to a well-diversified portfolio.
Achilles Therapeutics Fundamentals Growth
Achilles Stock prices reflect investors' perceptions of the future prospects and financial health of Achilles Therapeutics, and Achilles Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Achilles Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | (19.21 M) | ||||
| Shares Outstanding | 41.1 M | ||||
| Price To Earning | 0.49 X | ||||
| Price To Book | 0.59 X | ||||
| EBITDA | (70.44 M) | ||||
| Cash And Equivalents | 201.6 M | ||||
| Cash Per Share | 4.94 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 2.51 X | ||||
| Cash Flow From Operations | (48.45 M) | ||||
| Earnings Per Share | (1.66) X | ||||
| Total Asset | 161.46 M | ||||
| Retained Earnings | (259.95 M) | ||||
About Achilles Therapeutics Performance
By examining Achilles Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Achilles Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Achilles Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company was founded in 2016 and is headquartered in London, the United Kingdom. Achilles Therapeutics is traded on NASDAQ Exchange in the United States.Things to note about Achilles Therapeutics PLC performance evaluation
Checking the ongoing alerts about Achilles Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Achilles Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Achilles Therapeutics may become a speculative penny stock | |
| Achilles Therapeutics had very high historical volatility over the last 90 days | |
| Achilles Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (69.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Achilles Therapeutics PLC currently holds about 201.6 M in cash with (48.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Achilles Therapeutics stock hits 52-week high at 1.41 - Investing.com |
- Analyzing Achilles Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Achilles Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Achilles Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Achilles Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Achilles Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Achilles Therapeutics' stock. These opinions can provide insight into Achilles Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Achilles Stock
If you are still planning to invest in Achilles Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Achilles Therapeutics' history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |